Who owns Avalo Therapeutics, Inc.?
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from company filings.
Institutional ownership of AVTX from SEC Form 13F filings across 125 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
As of the 2026-06-30 reporting period, 125 institutions disclosed 70.8M shares of Avalo Therapeutics, Inc. worth $1.31B — about 162.3% of shares outstanding; the largest disclosed holder is FMR LLC. Source: SEC Form 13F filings, parsed by EvidInvest.
125
13F holders
$1.31B
value, 2026 filers
162.3%
of shares outstanding (70.8M sh)
55
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30 · % of fund = share of the manager's own book · % of co. = share of AVTX's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | FMR LLC | 5.1M | $94.3M | 0.0% | 11.7% | +77.1% |
| 2 | BlackRock, Inc. | 4.4M | $80.7M | 0.0% | 10% | +1234.7% |
| 3 | Deep Track Capital, LPNEW | 3.6M | $66.7M | 1.0% | 8.3% | new |
| 4 | Caligan Partners LP | 3.2M | $58.5M | 2.8% | 7.3% | +93.5% |
| 5 | TCG Crossover Management, LLC | 3.0M | $55.8M | 1.3% | 6.9% | +308.6% |
| 6 | Affinity Asset Advisors, LLC | 2.9M | $53.6M | 2.4% | 6.7% | +116.3% |
| 7 | STATE STREET CORP | 2.9M | $53.4M | 0.0% | 6.6% | +3932.3% |
| 8 | FARALLON CAPITAL MANAGEMENT, L.L.C. | 2.5M | $46.2M | 0.2% | 5.7% | +172.7% |
| 9 | Point72 Asset Management, L.P. | 2.4M | $44.1M | 0.0% | 5.5% | +160.6% |
| 10 | Avoro Capital Advisors LLC | 2.3M | $43.1M | 0.4% | 5.4% | +65.5% |
| 11 | VANGUARD CAPITAL MANAGEMENT LLC | 2.3M | $41.8M | 0.0% | 5.2% | +214.6% |
| 12 | BVF INC/IL | 2.1M | $38.4M | 1.0% | 4.8% | +27.1% |
| 13 | BANK OF AMERICA CORP /DE/ | 1.9M | $35.4M | 0.0% | 4.4% | +197.6% |
| 14 | Nantahala Capital Management, LLC | 1.9M | $34.4M | 1.1% | 4.3% | +50.8% |
| 15 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 1.7M | $32.0M | 0.0% | 4% | +102.5% |
| 16 | Soleus Capital Management, L.P. | 1.7M | $30.6M | 1.1% | 3.8% | +274.4% |
| 17 | BRAIDWELL LPNEW | 1.6M | $30.1M | 1.1% | 3.7% | new |
| 18 | PRICE T ROWE ASSOCIATES INC /MD/NEW | 1.3M | $24.2M | 0.0% | 3% | new |
| 19 | ALLIANCEBERNSTEIN L.P.NEW | 1.3M | $23.3M | 0.0% | 2.9% | new |
| 20 | UBS Group AG | 1.2M | $22.3M | 0.0% | 2.8% | +5.9% |
| 21 | Logos Global Management LP | 1.1M | $21.3M | 0.9% | 2.6% | +283.3% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 1.1M | $20.4M | 0.0% | 2.5% | +550.5% |
| 23 | Commodore Capital LP | 1.0M | $18.8M | 1.1% | 2.3% | +110.8% |
| 24 | RA CAPITAL MANAGEMENT, L.P. | 1.0M | $18.5M | 0.2% | 2.3% | +50.8% |
| 25 | GOLDMAN SACHS GROUP INC | 946,320 | $17.5M | 0.0% | 2.2% | +1474.4% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.